Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Income towards Parent Company (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Income towards Parent Company for 7 consecutive years, with -$6.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Income towards Parent Company rose 28.66% to -$6.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$38.2 million, a 23.25% increase, with the full-year FY2024 number at -$38.2 million, up 21.66% from a year prior.
  • Income towards Parent Company was -$6.7 million for Q4 2024 at Actinium Pharmaceuticals, up from -$11.6 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$5.1 million in Q2 2021 to a low of -$24.9 million in Q4 2021.
  • A 4-year average of -$10.3 million and a median of -$9.6 million in 2022 define the central range for Income towards Parent Company.
  • Peak YoY movement for Income towards Parent Company: skyrocketed 54.74% in 2022, then tumbled 124.32% in 2023.
  • Actinium Pharmaceuticals' Income towards Parent Company stood at -$24.9 million in 2021, then surged by 54.74% to -$11.3 million in 2022, then rose by 17.42% to -$9.3 million in 2023, then grew by 28.66% to -$6.7 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Income towards Parent Company are -$6.7 million (Q4 2024), -$11.6 million (Q3 2024), and -$11.4 million (Q2 2024).